issuer’s proposal to the JTS254A bondholders’ meeting to adjust the bond repayment terms, which involves a deferral or change in the debt repayment schedule. For the JTS254A bond, the company stated in the
www.interpharma.co.th IP_OCS/011/2020 8th June 2020 Subject: Notify the Resolutions of the Board of Directors Meeting, Change of Objectives of Funds Usage, Acquisition of Assets, The Issuance of Debentures and Fix the
Normalize.css to remove // styles targeting irrelevant browsers while applying new styles. // // Normalize is licensed MIT. https://github.com/necolas/normalize.css // Document // // 1. Change from `box-sizing
) to review and adjust the assumptions for cash flows projections of those subsidiaries to calculate the recoverable amount appropriately, and to consider the adequacy and appropriateness of the
Public Company Limited and its subsidiaries had the operation results for the 6-month period ended 30 June 2020 with the following details: unit: THB million 2020 2019 Change (THB mill.) Change (%) Revenue
-9.30 -138.48 Change +/(-) Unit : million baht • Revenue of Q 1/2019 is less than of both Q 4/2018 and Q1/2018 because of the followings: o Low purchasing power in domestic market causes our domestic
bunch (FFB) in April 2020. As CPO expeditiously increased as mentioned above, the Company could not adjust selling price to keep up with the CPO market price; therefore cost of sales ratio increased from
Gross Profit Selling Admin Net(loss) profit Q1/17 212,140 78,137 19,861 24,659 21,584 Q1/18 213,552 76,707 21,974 18,709 27,898 % Change 0.67 (1.83) 10.64 (24.13) 29.25 In overall, the Company and its
date on January 1, 2020. By this summarization of business operation and financial statement of year 2019 was prepared under standard before the change and does not have retrospective improvements on